Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl‑1H‑pyrazol‑5‑yl)pyrimidine‑2,4‑diamine is a synthetic small molecule belonging to the benzimidazole class. It is an experimental compound primarily studied as an inhibitor of the serine/threonine-protein kinase/endoribonuclease IRE1 (also known as inositol-requiring enzyme 1). IRE1 is a key sensor and mediator of the unfolded protein response (UPR) in endoplasmic reticulum stress. By inhibiting IRE1’s kinase activity, this compound may modulate cellular stress responses relevant to cancer and other diseases involving ER stress pathways. The compound has not been approved for clinical use and remains at the experimental stage[1][7][9].
- Other names
- N2-(1H-benzimidazol-5-yl)-N4-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamineN2-(1H-benzo[d]imidazol-6-yl)-N4-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine 2,4-diamine
02
Targets
ERN1 (Inositol-requiring enzyme 1 alpha)
Beyond the preview
Go deeper on N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine.